Monogram Biosciences' Novel Drug testing utilizes all of the PhenoSense™ HIV assays designed to evaluate the activity of protease (PR), reverse transcriptase (RT), integrase inhibitors or entry inhibitors and to measure changes in drug susceptibility of patient viruses to these inhibitors. The Novel Drug testing assays can help evaluate cross-resistance in HIV-1 with reduced susceptibility to FDA-approved drugs by using either patient-derived viruses from Monogram's library or viruses (present in patient plasma or tissue culture supernatants, or other sources) supplied by the client. The extent of cross-resistance can be a preliminary indicator of the possible utility of the novel compound(s) for treatment of patients. Novel compounds undergo preliminary testing to determine the optimal start concentration and drug dilutions to use in the assay to achieve maximum accuracy and reproducibility. Testing and data analysis are conducted under standard laboratory procedures in Monogram's CLIA-certified and CAP-certified clinical reference laboratory.

Monogram can also build site-directed mutants (SDMs) and incorporate them into a panel of viruses to be tested against a set of novel compounds.

Drug Profiling - As part of the Novel Drug offering, clients also have the option to include their novel compound in Monogram's standard PhenoSense PR/RT panel during routine clinical lab testing. The novel drug data are reported only to the submitting client along with the daily PhenoSense results thereby providing a direct comparison of the novel compound to all commercially available drugs.

Reference: Bethell et al. Antivir Chem Chemother. 2005;16(5):295-302.

Click on the titles below to download the clinical posters:

• Gilead Poster 1 | 2
• Sequoia Poster 1

For more information, please contact: collaborations@monogrambio.com